Redmile Group LLC 13D and 13G filings for Stoke Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 9:00 pm Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 4,713,509 9.000% | 2,088,003 (+79.53%) | Filing |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 2,625,506 5.900% | -1,541,469 (-36.99%) | Filing |
| 2023-02-03 5:16 pm Purchase | 2022-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 4,166,975 9.700% | 1,920,307 (+85.47%) | Filing |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 2,246,668 6.100% | -439,566 (-16.36%) | Filing |
| 2021-02-16 4:09 pm Purchase | 2020-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 2,686,234 7.400% | 2,686,234 (New Position) | Filing |